Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
Status:
Terminated
Trial end date:
2014-06-18
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and efficacy of the use of bendamustine
in combination with a commonly used combination chemotherapy to treat relapsed and refractory
multiple myeloma. The study will be conducted in two phases. Participants in phase I will
receive 1 of 4 escalating doses of bendamustine. Once the maximum tolerated dose of
bendamustine is determined, phase II of this trial will begin. Participants in phase II will
receive the maximum tolerated dose of bendamustine in combination with standard of care
chemotherapy.